Obesity Pharmacotherapy: A Practical Approach to Patient-Centered Medication Selection
10.21215/kjfp.2025.15.4.194
- Author:
Jungha PARK
1
Author Information
1. Department of Family Medicine, Kyung Hee Medical Center, College of Medicine, Kyung Hee University, Seoul, Korea
- Publication Type:Review Article
- From:
Korean Journal of Family Practice
2025;15(4):194-201
- CountryRepublic of Korea
- Language:English
-
Abstract:
Obesity pharmacotherapy has substantial advanced in recent times, broadening the available treatment options. The currently available anti-obesity medications in Korea are classified as short- or long-term approved agents. The short-term approved medications are sympathetic amines, whereas the long-term approved medications have diverse mechanisms of action. The recently developed semaglutide and tirzepatide demonstrate superior efficacy, whereas other agents offer various distinct advantages. Anti-obesity medication selection should be individualized based on patient characteristics including budget, comorbidities, age, dietary patterns, and side effects. Although all anti-obesity medications reduce muscle mass to some extent, adequate protein intake and exercise are crucial regardless of the agent chosen. Patient education regarding realistic weight loss goals, gradual dose titration, and long-term treatment commitment is essential for successful outcomes. This review provides practical guidance for clinicians regarding patient-centered selection and safe prescription of anti-obesity medications.
